Trade Summary

4 months ago, Akkaraju Srinivas, serving as Dir, 10% owner at Kalaris Therapeutics, Inc. (KLRS), purchased 479,847 shares at $10.42 per share, for a total transaction value of $5,000,006.00. Following this transaction, Akkaraju Srinivas now holds 12,948,081 shares of KLRS.

This purchase represents a 4.00% increase in Akkaraju Srinivas's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, December 18, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, February 17, 2026, 61 days after the trade was made.

Kalaris Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.